Market revenue in 2024 | USD 9,231.6 million |
Market revenue in 2030 | USD 16,218.1 million |
Growth rate | 9.9% (CAGR from 2025 to 2030) |
Largest segment | Psoriasis |
Fastest growing segment | Psoriasis |
Historical data covered | 2018 - 2023 |
Base year for estimation | 2024 |
Forecast period covered | 2025 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Acne, Psoriasis, Rosacea, Alopecia |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to dermatological drugs market will help companies and investors design strategic landscapes.
Psoriasis was the largest segment with a revenue share of 39.54% in 2024. Horizon Databook has segmented the North America dermatological drugs market based on acne, psoriasis, rosacea, alopecia covering the revenue growth of each sub-segment from 2018 to 2030.
The dermatological drugs market in North America is experiencing steady growth, driven by the increasing prevalence of skin conditions and the rising demand for both therapeutic and aesthetic treatments. The U.S. and Canada, being major markets in the region, benefit from advanced healthcare infrastructure, a high level of healthcare spending, and a large patient base. The region's well-established pharmaceutical industry also supports the growth and distribution of dermatological treatments.
Key drivers in the North American dermatological drugs market include the increasing incidence of skin conditions such as acne, eczema, psoriasis, and alopecia. The rising awareness of dermatological conditions, combined with advancements in drug formulations and treatment options, is fueling the demand for dermatological drugs.
Additionally, the growth in telemedicine adoption for dermatology consultations is enhancing access to care and further expanding the market reach. The approval of new treatments is a critical factor contributing to market growth. For instance, in June 2023, Pfizer’s LITFULO (ritlecitinib), a once-daily oral treatment for severe alopecia areata, received FDA approval for adolescents (12+) and adults.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America dermatological drugs market , including forecasts for subscribers. This continent databook contains high-level insights into North America dermatological drugs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account